依达拉奉右莰醇联合脑蛋白水解物治疗急性脑梗死的临床研究

目的 探讨依达拉奉右莰醇联合脑蛋白水解物治疗急性脑梗死的临床疗效。方法 选取2021年10月—2022年10月唐山市工人医院收治的84例急性脑梗死患者，按照随机数字表法分为对照组和治疗组，每组各42例。对照组患者静脉滴注予脑蛋白水解物注射液，取250 mL生理盐水，加入脑蛋白水解物注射液10 mL,1次/d；治疗组在对照组基础上静脉滴注依达拉奉右莰醇注射用浓溶液，15 mL加入100 mL生理盐水，2次/d。两组均连续用药2周。观察两组的临床疗效，比较两组治疗前后美国国立卫生研究院卒中量表（NIHSS）评分、神经生长因子（NGF）、基质金属蛋白酶-9(MMP-9)及N-末端脑钠肽前体（NT-proBNP）的变化情况。结果 治疗后，治疗组总有效率是92.86%，显著高于对照组的71.73%(P<0.05)。治疗1、2周两组NIHSS评分均较治疗前有所下降（P<0.05），且治疗组下降程度更明显（P<0.05）。治疗后，两组血清NGF较治疗前显著上升，MMP-9、NT-proBNP水平均较治疗前下降（P<0.05），且治疗组血清细胞因子水平改善更显著（P<0....

Clinical study of edaravone and dexborneol combined with cerebroprotein hydrolysate in treatment of acute cerebral infarction

Objective To investigate the effect of edaravone and dexborneol combined with cerebroprotein hydrolysate in treatment of acute cerebral infarction. Methods A total of 84 patients with acute cerebral infarction admitted to Tangshan Workers'' Hospital from October 2021 to October 2022 were selected and divided into control group and treatment group according to random number table method, with 42 patients in each group. Patients in the control group were iv administered with Cerebroprotein Hydrolysate Injection, 10 mL was added into 250 mL normal saline, once daily. Patients in the treatment group were iv administered with Edaravone and Dexborneol Concentrated Solution for injection on the basis of the control group, 15 mL was added into 100 mL normal saline, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of National Institutes of Health Stroke Scale (NIHSS) score, nerve growth factor (NGF), matrix metalloproteinase-9 (MMP-9) and N-terminal brain natriuretic peptide precursor (NT-proBNP) were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 92.86%, significantly higher than that of the control group (71.73%) (P < 0.05). After 1 week and 2 weeks of treatment, the NIHSS scores in both groups were decreased compared with those before treatment (P < 0.05), and the decrease in the treatment group was more significant (P < 0.05). After treatment, serum NGF of the two groups was significantly increased compared with that before treatment, but the levels of MMP-9 and NT-proBNP were decreased compared with that before treatment (P < 0.05), and the serum cytokine levels in the treatment group were more significantly improved (P < 0.05). Conclusion Edaravone and dexborneol combined with cerebroprotein hydrolysate has remarkable curative effect in treatment of acute cerebral infarction, and can effectively promote the recovery of neurological function in patients, and can improve serum NGF, reduce the level of MMP-9 and NT-proBNP with safe and reliable, which is worthy of clinical promotion and use.